Iambic Therapeutics develops cancer medicines using physics-informed AI and automated experiments, connecting molecular design with predictions of how drugs behave in people.
Products & media
A multimodal model that predicts drug behavior in people from preclinical and early clinical data.
An investigational, brain-penetrant HER2 inhibitor in Phase 1/1b development for advanced solid tumors.
An investigational dual CDK2/4 inhibitor undergoing IND-enabling development for cancer.
A co-folding model for predicting interactions between proteins and potential drug molecules; a public preview supports research.
An investigational KIF18A inhibitor undergoing IND-enabling development for cancer.
Cosigns
“Iambic has integrated BioNeMo and other emerging NVIDIA technologies into its platform to accelerate the creation of an oncology candidate”
Team
Current Affiliates
1 person
Jobs
See all jobs for Iambic Therapeutics here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Data current as of November 10, 2025
Leads
Participating Firms
Angels